Eyenovia Total Liabilities 2016-2025 | HYPD
Eyenovia total liabilities from 2016 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.
Eyenovia Annual Total Liabilities
(Millions of US $) |
| 2024 |
$17 |
| 2023 |
$20 |
| 2022 |
$14 |
| 2021 |
$11 |
| 2020 |
$19 |
| 2019 |
$3 |
| 2018 |
$3 |
| 2017 |
$1 |
| 2016 |
$0 |
| 2015 |
$0 |
Eyenovia Quarterly Total Liabilities
(Millions of US $) |
| 2025-03-31 |
$16 |
| 2024-12-31 |
$17 |
| 2024-09-30 |
$19 |
| 2024-06-30 |
$21 |
| 2024-03-31 |
$24 |
| 2023-12-31 |
$20 |
| 2023-09-30 |
$19 |
| 2023-06-30 |
$19 |
| 2023-03-31 |
$13 |
| 2022-12-31 |
$14 |
| 2022-09-30 |
$11 |
| 2022-06-30 |
$12 |
| 2022-03-31 |
$10 |
| 2021-12-31 |
$11 |
| 2021-09-30 |
$21 |
| 2021-06-30 |
$22 |
| 2021-03-31 |
$17 |
| 2020-12-31 |
$19 |
| 2020-09-30 |
$7 |
| 2020-06-30 |
$3 |
| 2020-03-31 |
$3 |
| 2019-12-31 |
$3 |
| 2019-09-30 |
$2 |
| 2019-06-30 |
$2 |
| 2019-03-31 |
$3 |
| 2018-12-31 |
$3 |
| 2018-09-30 |
$2 |
| 2018-06-30 |
$1 |
| 2018-03-31 |
$1 |
| 2017-12-31 |
$1 |
| 2017-09-30 |
$7 |
| 2017-06-30 |
$0 |
| 2017-03-31 |
$0 |
| 2016-12-31 |
|
| 2016-09-30 |
$0 |
| 2015-12-31 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.041B |
$0.000B |
|
Eyenovia, Inc. is a clinical stage biopharmaceutical company which engages in developing therapeutics for the treatment of prominent eye diseases primarily in the United States. Its product portfolio includes MicroProst, MicroStat, MicroTears and MicroPine which are in clinical stage. Eyenovia, Inc. is based in New York.
|
